

CITATION REPORT

List of articles citing

Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

DOI: 10.1007/s40265-016-0553-8
Drugs, 2016, 76, 523-31.

Source: <https://exaly.com/paper-pdf/65483276/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
17	Advancements in nano-enabled therapeutics for neuroHIV management. <i>International Journal of Nanomedicine</i> , 2016 , 11, 4317-25	7.3	29
16	Molecular medicine - To be or not to be. <i>Biophysical Chemistry</i> , 2016 , 214-215, 33-46	3.5	2
15	Dual antiretroviral therapy for HIV infection. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 923-932	4.1	35
14	Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. <i>Lancet HIV</i> , 2017 , 4, e384-e392	7.8	48
13	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. <i>Lancet, The</i> , 2018 , 391, 839-849	4.0	214
12	GSK3732394: a Multi-specific Inhibitor of HIV Entry. <i>Journal of Virology</i> , 2019 , 93,	6.6	8
11	Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. <i>BMC Infectious Diseases</i> , 2019 , 19, 59	4	13
10	Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection. <i>Annals of Pharmacotherapy</i> , 2019 , 53, 860-866	2.9	5
9	Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1928-1929	11.6	75
8	Using Microbubbles as Targeted Drug Delivery to Improve AIDS. 2020 ,		
7	Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1332-1337	5.1	5
6	Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 84, 60-65	3.1	3
5	Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 87, 701-702	3.1	3
4	Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults. <i>Annals of Pharmacotherapy</i> , 2021 , 10600280211034176	2.9	4
3	Less is more: A novel single-tablet regimen with two-drugs, dolutegravir/lamivudine. <i>Drug Discoveries and Therapeutics</i> , 2021 , 15, 225-226	5	0
2	Uptake Success and Cost Savings from Switching to a Two-Drug Antiretroviral Regimen.. <i>AIDS Patient Care and STDs</i> , 2021 ,	5.8	
1	Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naïve adults with HIV-1 infection.. <i>BMC Infectious Diseases</i> , 2022 , 22, 17	4	0

